Appropriate treatment
PreclinicalSmall molecule
Appropriate treatment is one of 17 small molecule programs targeting Chronic Lung Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Chronic Lung Disease
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Pulmicort
SSalix
Approved
Aldactone
PfizerPhase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Qvar
Chiesi Farmaceutici S.p.A.Phase 3
Inomax
MMallinckrodt
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Spiriva
Boehringer IngelheimPhase 3
Viagra
VViatris Specialty LLC
Phase 3
Ino
UUniversity of Colorado, Denver
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Appropriate treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details